BRPI0518448A2 - composiÇÕes farmacÊuticas compreendendo um derivado de camptotecina - Google Patents

composiÇÕes farmacÊuticas compreendendo um derivado de camptotecina

Info

Publication number
BRPI0518448A2
BRPI0518448A2 BRPI0518448-7A BRPI0518448A BRPI0518448A2 BR PI0518448 A2 BRPI0518448 A2 BR PI0518448A2 BR PI0518448 A BRPI0518448 A BR PI0518448A BR PI0518448 A2 BRPI0518448 A2 BR PI0518448A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
camptothecin derivative
derivative
camptothecin
camptotecin
Prior art date
Application number
BRPI0518448-7A
Other languages
English (en)
Inventor
Isabel Ottinger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35691476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0518448(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0518448A2 publication Critical patent/BRPI0518448A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSIÇÕES FARMACÊUTICAS COMPREENDENDO UM DERIVADO DE CAMPTOTECINA. A presente invenção refere-se a novas composições farmacêuti- cas em que o agente ativo é um inibidor de topoisomerase 1, em particular, um derivado de camptotecina, que é útil para o tratamento e prevenção de doenças proliferativas incluindo câncer
BRPI0518448-7A 2004-11-19 2005-11-17 composiÇÕes farmacÊuticas compreendendo um derivado de camptotecina BRPI0518448A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62975704P 2004-11-19 2004-11-19
PCT/EP2005/012334 WO2006053755A1 (en) 2004-11-19 2005-11-17 Pharmaceutical compositions comprising a camtothecin derivate

Publications (1)

Publication Number Publication Date
BRPI0518448A2 true BRPI0518448A2 (pt) 2008-11-18

Family

ID=35691476

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518448-7A BRPI0518448A2 (pt) 2004-11-19 2005-11-17 composiÇÕes farmacÊuticas compreendendo um derivado de camptotecina

Country Status (28)

Country Link
US (1) US8518961B2 (pt)
EP (1) EP1814520B1 (pt)
JP (1) JP4982378B2 (pt)
KR (1) KR101283840B1 (pt)
CN (1) CN101056619A (pt)
AR (1) AR052033A1 (pt)
AU (1) AU2005306018B2 (pt)
BR (1) BRPI0518448A2 (pt)
CA (1) CA2584343C (pt)
DK (1) DK1814520T3 (pt)
ES (1) ES2572133T3 (pt)
GT (1) GT200500310A (pt)
HR (1) HRP20160446T1 (pt)
HU (1) HUE027135T2 (pt)
IL (1) IL182703A (pt)
MA (1) MA29076B1 (pt)
MX (1) MX2007005897A (pt)
MY (1) MY148647A (pt)
NO (1) NO342592B1 (pt)
NZ (1) NZ554551A (pt)
PE (1) PE20061077A1 (pt)
PL (1) PL1814520T3 (pt)
RU (3) RU2007122470A (pt)
SI (1) SI1814520T1 (pt)
TN (1) TNSN07193A1 (pt)
TW (1) TWI368521B (pt)
WO (1) WO2006053755A1 (pt)
ZA (1) ZA200703148B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
ITRM20050418A1 (it) * 2005-08-04 2007-02-05 Sigma Tau Ind Farmaceuti Sistemi terapeutici a rilascio immediato per il migliorato assorbimento orale di 7-[(e)-t-butilossimminometil] camptotecina.
WO2007017514A1 (en) * 2005-08-10 2007-02-15 Novartis Ag Microparticle compositions of the topoisomerase i inhibitor 7-tert-butoxyiminomethylcamptothecin
JP2010508357A (ja) * 2006-10-31 2010-03-18 ワイス エルエルシー ホスホリパーゼ酵素阻害剤の処方
US20100070052A1 (en) * 2008-08-19 2010-03-18 Robb Fujioka System and method for providing applications and peripherals to a fixed price component-based computing platform
EP2588081A4 (en) 2010-06-29 2014-12-10 Verastem Inc ORAL FORMULATION OF CHINESE INHIBITORS
MX343894B (es) 2010-06-30 2016-11-28 Poniard Pharmaceuticals Inc * Síntesis y uso de inhibidores de cinasa.
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
AU2019404026B2 (en) * 2018-12-19 2023-06-08 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
KR20230017829A (ko) 2020-05-27 2023-02-06 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 수용체 조절제 렐라코릴란트 및 cyp2c8과 cyp3a4의 이중 기질인 파클리탁셀의 병용 투여
AU2022339721B2 (en) * 2021-09-05 2025-02-27 Tairx, Inc. Formulations with enhanced sn-38 solubility and oral absorption
WO2024042523A1 (en) * 2022-08-24 2024-02-29 Lyotropic Delivery Systems Ltd. Oral delivery of active compounds for treating glycogen storage diseases
WO2024077169A1 (en) 2022-10-06 2024-04-11 Corcept Therapeutics Incorporated Formulations of glucocorticoid receptor modulators
US12433882B2 (en) 2022-10-28 2025-10-07 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
JPH08504811A (ja) * 1992-12-24 1996-05-28 ヘマジェン／ピーエフシー フルオロカーボンのエマルジョン
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5597829A (en) * 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
CN1208047C (zh) * 1997-07-29 2005-06-29 法玛西雅厄普约翰美国公司 亲脂性化合物的自体乳化剂
AR013261A1 (es) 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
EP1075252A2 (en) 1998-05-07 2001-02-14 ELAN CORPORATION, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
US20030059465A1 (en) 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
EP1044977B1 (en) * 1999-03-09 2002-05-02 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Camptothecin derivatives having antitumor activity
IT1306129B1 (it) * 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
WO2000071163A1 (en) 1999-05-24 2000-11-30 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9918885D0 (en) 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US20040009229A1 (en) 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
GB0001928D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
US20020150615A1 (en) * 2001-02-12 2002-10-17 Howard Sands Injectable pharmaceutical composition comprising microdroplets of a camptothecin
US6653319B1 (en) 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
EP1478343B1 (en) 2001-10-15 2017-03-22 Crititech, Inc. Compositions and methods for delivery of poorly water soluble drugs and methods of treatment
WO2003057128A2 (en) 2001-12-11 2003-07-17 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
JP2003267891A (ja) 2002-03-13 2003-09-25 Mitsubishi-Kagaku Foods Corp Ｗ／ｏ／ｗ型エマルション製剤
CZ294371B6 (cs) 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
EP1393719A1 (en) * 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
JP4426749B2 (ja) 2002-07-11 2010-03-03 株式会社産学連携機構九州 Ｏ／ｗ型エマルション製剤
US20040171560A1 (en) 2002-12-23 2004-09-02 Dabur Research Foundation Stabilized pharmaceutical composition
JP2006199590A (ja) 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
WO2005042539A1 (en) 2003-10-29 2005-05-12 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
US20050191343A1 (en) * 2003-11-26 2005-09-01 Shire Laboratories, Inc. Micellar systems useful for delivery of lipophilic or hydrophobic compounds
EP1694242B1 (en) 2003-12-17 2014-04-16 Bionumerik Pharmaceuticals, Inc. Process for making pharmaceutical 7-(2-trimethylsilylethyl) camptothecin formulations
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos

Also Published As

Publication number Publication date
MY148647A (en) 2013-05-15
KR20070084357A (ko) 2007-08-24
ES2572133T3 (es) 2016-05-30
NZ554551A (en) 2010-01-29
MA29076B1 (fr) 2007-12-03
ZA200703148B (en) 2008-09-25
AU2005306018B2 (en) 2009-12-17
HUE027135T2 (en) 2016-08-29
JP2008520606A (ja) 2008-06-19
WO2006053755A1 (en) 2006-05-26
HRP20160446T1 (hr) 2016-05-20
SI1814520T1 (sl) 2016-06-30
CA2584343C (en) 2013-09-24
TNSN07193A1 (en) 2008-11-21
RU2620331C2 (ru) 2017-05-24
GT200500310A (es) 2006-06-19
AR052033A1 (es) 2007-02-28
AU2005306018A1 (en) 2006-05-26
RU2012120388A (ru) 2013-11-27
US20080125450A1 (en) 2008-05-29
JP4982378B2 (ja) 2012-07-25
TWI368521B (en) 2012-07-21
PE20061077A1 (es) 2006-11-13
IL182703A0 (en) 2007-09-20
CA2584343A1 (en) 2006-05-26
KR101283840B1 (ko) 2013-07-15
EP1814520B1 (en) 2016-04-13
US8518961B2 (en) 2013-08-27
DK1814520T3 (en) 2016-05-30
RU2015131700A (ru) 2017-02-02
IL182703A (en) 2015-11-30
PL1814520T3 (pl) 2016-08-31
TW200631606A (en) 2006-09-16
EP1814520A1 (en) 2007-08-08
RU2007122470A (ru) 2008-12-27
CN101056619A (zh) 2007-10-17
MX2007005897A (es) 2007-06-19
NO20072258L (no) 2007-08-10
NO342592B1 (no) 2018-06-18

Similar Documents

Publication Publication Date Title
TNSN07193A1 (en) Pharmaceutical compositions comprising a camptothecin derivate
BRPI1015539A2 (pt) composições e métodos para tratamento de queimaduras
CR9427A (es) Combinacion terapeutica en casos de hiperplasia prostatica benigna
GT200500137A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis.
BRPI0407922A (pt) derivados de isoquinolina e métodos de uso destes
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
CR20110016A (es) Compuestos quimicos 251
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
NI201000033A (es) Amidas heterocíclicas útiles para el tratamiento de cáncer y psoriasis
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
CR10305A (es) "derivados sustituidos de cromanol y su uso.
ATE428411T1 (de) Hdl-verstärkende kombinationstherapie-komplexe
HN2001000037A (es) Derivados de eteres de pirazol como agentes antiinflamatorios/analgesicos
EP1819227A4 (en) PHARMACEUTICAL FORMULATIONS OF DECITABIN
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
NZ598489A (en) Combination therapy for treating proliferative diseases
BR112012022243A8 (pt) Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
BRPI0713743B8 (pt) composto, e, composição farmacêutica
PA8627601A1 (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitos
WO2006108679A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use to combat cancer

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL